These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11173190)

  • 1. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis.
    White RL; Friedrich LV; Manduru M; Mihm LB; Bosso JA
    Diagn Microbiol Infect Dis; 2001 Jan; 39(1):39-47. PubMed ID: 11173190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group.
    García-Rodriguez JA; García Sánchez JE; Trujillano I; Sánchez de San Lorenzo A
    J Antimicrob Chemother; 1991 May; 27(5):599-606. PubMed ID: 1885418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.
    White R; Friedrich L; Burgess D; Warkentin D; Bosso J
    Antimicrob Agents Chemother; 1996 Apr; 40(4):904-8. PubMed ID: 8849249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The postantibiotic effect of meropenem and imipenem on selected bacteria.
    Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The postantibiotic effect of imipenem: relationship with drug concentration, duration of exposure, and MIC.
    Munckhof WJ; Olden D; Turnidge JD
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1735-7. PubMed ID: 9257751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multicenter study of the in vitro effect of imipenem (N-formimidoyl-thienamycin) on hospital bacteria].
    Soussy CJ; Otterbein G; Le Van Thoi J; Thabaut A; Meyran M; Courtieu AL; Reynaud A; Dabernat H; Lareng MB; Chanal M
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):487-92. PubMed ID: 3911142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Can meropenem E-test be used to estimate the presence of carbapenem resistance gene cfiA among Bacteroides fragilis strains?].
    Toprak Ülger N; Ilki A; Ozel N; Balkan N; Söyletir G
    Mikrobiyol Bul; 2011 Jul; 45(3):385-91. PubMed ID: 21935771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem-induced alteration of the susceptibility of Escherichia coli and Staphylococcus aureus to the bactericidal activity of human polymorphonuclear leucocytes.
    Herrera-Insúa I; Pérez P; Martínez P; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 1997 Feb; 39(2):223-8. PubMed ID: 9069543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1990; 13(1):57-61. PubMed ID: 2331851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of meropenem with humoral and phagocytic defences.
    Easmon CS
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():259-64. PubMed ID: 2681125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial effects of meropenem and imipenem against Haemophilus influenzae.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1991; 37(1):38-42. PubMed ID: 2013240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
    Sumita Y; Fukasawa M
    J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
    Peterson ML; Hovde LB; Wright DH; Brown GH; Hoang AD; Rotschafer JC
    Antimicrob Agents Chemother; 2002 Jan; 46(1):203-10. PubMed ID: 11751135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Determination of Minimum Inhibitory Concentration of Aqueous Garlic Extract and Imipenem against Staphylococcus aureus and Escherichia coli.
    Saha SK; Saha S; Akhter SM; Khatun S; Islam MM; Roy P
    Mymensingh Med J; 2016 Jul; 25(3):477-84. PubMed ID: 27612894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basis for nebulized antibiotics: droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
    Todisco T; Eslami A; Baglioni S; Sposini T; Tascini C; Sommer E; Knoch M
    J Aerosol Med; 2000; 13(1):11-6. PubMed ID: 10947319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W; Pitkin DH; Nadler H
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
    Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
    Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.